Comprehensive echocardiographic prediction of postprocedural transmitral pressure gradient following transcatheter mitral valve repair.


Journal

The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 27 03 2021
accepted: 15 05 2021
pubmed: 29 5 2021
medline: 16 10 2021
entrez: 28 5 2021
Statut: ppublish

Résumé

Iatrogenic mitral stenosis following transcatheter mitral valve repair (TMVR) for relevant mitral regurgitation (MR) is a potential adverse side-effect, known to affect long-term outcome. However, only few determinants of an elevated mean transmitral pressure gradient (TMPG) have been described thus far. We sought to develop an integrative model for the prediction of TMPG following MitraClip (MC) therapy. From 01/2013 to 03/2017, a total of 175 consecutive patients were successfully (MR ≤ 2 + at discharge) treated with a MitraClip implantation at our centre. Of these, a total of 148 patients (54% male, 77.0 ± 6.0 years, 58% with secondary MR) had complete echocardiographic data sets comprising pre- and postinterventional two- and three-dimensional transthoracic (TTE) and transoesophageal (TOE) echocardiograms. Comprehensive studies of predefined parameters were performed. An expert-based prediction model including preprocedural variables (annular ellipticity, mitral valve commissure-to-commissure diameter, preprocedural transmitral pressure gradient and MR aetiology) was set up and validated with a total of 200 bootstrap samples. A nomogram was developed to predict the postprocedural TMPG based on selected echocardiographic variables. Introduction of nomogram-based guiding of MC therapy could help identify patients at risk for postprocedural mitral stenosis, have an influence on preprocedural patient selection and intraprocedural decision making.

Identifiants

pubmed: 34046774
doi: 10.1007/s10554-021-02290-4
pii: 10.1007/s10554-021-02290-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2947-2955

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Rudolph V, Knap M, Franzen O et al (2011) Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery. J Am Coll Cardiol 58:2190–2195
pubmed: 22078425
Puls M, Lubos E, Boekstegers P et al (2015) One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J 37:703–712
pubmed: 26614824 pmcid: 4761401
Sürder D, Pedrazzini G, Gaemperli O et al (2013) Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. Heart 99:1034–1040
pubmed: 23343688
Lubos E, Schlüter M, Vettorazzi E et al (2014) MitraClip therapy in surgical high-risk patients: identification of echocardiographic variables affecting acute procedural outcome. JACC Cardiovasc Interv 7:394–402
pubmed: 24630887
Rudolph V, Lubos E, Schlüter M et al (2013) Aetiology of mitral regurgitation differentially affects 2-year adverse outcomes after MitraClip therapy in high-risk patients. Eur J Heart Fail 15:796–807
pubmed: 23426023
Toggweiler S, Zuber M, Sürder D et al (2014) Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: Durability of the procedure and predictors of outcome. Open Heart 1:e000056
pubmed: 25332799 pmcid: 4195933
Paranskaya L, D’Ancona G, Bozdag-Turan I et al (2013) Residual mitral valve regurgitation after percutaneous mitral valve repair with the MitraClip? System is a risk factor for adverse one-year outcome. Catheter Cardiovasc Interv 81:609–617
pubmed: 22887450
Neuss M, Schau T, Isotani A, Pilz M, Schöpp M, Butter C (2017) Elevated mitral valve pressure gradient after mitraclip implantation deteriorates long-term outcome in patients with severe mitral regurgitation and severe heart failure. JACC Cardiovasc Interv 10:931–939
pubmed: 28473116
Feldman T, Foster E, Glower DD et al (2011) Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364:1395–1406
pubmed: 21463154
Zoghbi WA, Enriquez-Sarano M, Foster E et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography. J Am Soc Echocardiogr 16:777–802
pubmed: 12835667
Foster E, Wasserman HS, Gray W et al (2007) Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair. Am J Cardiol 100(10):1577–1583
pubmed: 17996523
Vahanian A, Alfieri O, Andreotti F et al (2012) Guidelines on the management of valvular heart disease. Eur Heart J 33:2451–2496
pubmed: 22922415
Feldman T, Kar S, Elmariah S et al (2015) Randomized comparison of percutaneous repair and surgery for mitral regurgitation 5-year results of EVEREST II. J Am Coll Cardiol 66:2844–2854
pubmed: 26718672
Patzelt J, Zhang W, Sauter R et al (2019) Elevated mitral valve pressure gradient is predictive of long-term outcome after percutaneous edge-to-edge mitral valve repair in patients with degenerative mitral regurgitation (MR), but not in functional MR. J Am Heart Assoc 8:e011366
pubmed: 31248323 pmcid: 6662353
Boerlage-Van Dijk K, Van Riel ACMJ, De Bruin-Bon RHACM et al (2014) Mitral inflow patterns after mitraclip implantation at rest and during exercise. J Am Soc Echocardiogr 27:24–31
pubmed: 24161483
Singh GD, Smith TW, Rogers JH (2017) Mitral stenosis due to dynamic clip-leaflet interaction during the MitraClip procedure: case report and review of current knowledge. Cardiovasc Revasculariz Med 18:287–294
Biaggi P, Felix C, Gruner C et al (2013) Assessment of mitral valve area during percutaneous mitral valve repair using the MitraClip system comparison of different echocardiographic methods. Circulation 6:1032–1040
pubmed: 24134955
Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791

Auteurs

Hannes Alessandrini (H)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany. h.alessandrini@asklepios.com.

Peter Wohlmuth (P)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Felix Meincke (F)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Samer Hakmi (S)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Timm Ubben (T)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Sebastian Bohnen (S)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Theresa Wißt (T)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Karl-Heinz Kuck (KH)

LANS Medicum, Hamburg, Germany.

Stephan Willems (S)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Eike Tigges (E)

Department of Cardiology and Intensive Care, Asklepios Klinik St. Georg, Lohmühlenstrasse 5, 20099, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH